• Selonsertib fails to reduce pulmonary vascular resistance, improve outcomes in PAH

    10 days ago - By Healio

    In the phase 2 ARROW trial, selonsertib for 24 weeks failed to significantly reduce pulmonary vascular resistance or achieve clinical improvement in patients with pulmonary arterial hypertension.
    “Selonsertib is a first-in-class small-molecule inhibitor that has been developed for the treatment of diseases with a high burden of oxidative stress, including PAH,” Stephan Rosenkranz, MD, interventional cardiologist at the Heart Center and the Cologne Cardiovascular Research Center and head of the Pulmonary Hypertension Center at the University of
    Read more ...